Galantamine inhibits slowly inactivating K+ currents with a dual dose-response relationship in differentiated N1E-115 cells and in CA1 neurones

European Journal of Pharmacology

Volumn 634, Issue 1-3, 2010, Pages 16-25

  Vicente, M Inês ^a,b   Costa, Pedro F ^a   Lima, Pedro A ^a  

^a NOVA MEDICAL SCHOOL   (Portugal)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Galantamine; Hippocampus; Neuroblastoma; Voltage clamp artefact

Indexed keywords

GALANTAMINE; VOLTAGE GATED POTASSIUM CHANNEL; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE RESPONSE; ELECTROPHYSIOLOGY; HIPPOCAMPUS; MOUSE; NERVE CELL; NERVE CELL EXCITABILITY; NEUROBLASTOMA CELL; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; STEADY STATE; VOLTAGE CLAMP; ACTION POTENTIAL; ANIMAL; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; HIPPOCAMPAL CA1 REGION; PHYSIOLOGY; TUMOR CELL LINE;

ACTION POTENTIALS; ANIMALS; CA1 REGION, HIPPOCAMPAL; CELL DIFFERENTIATION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GALANTAMINE; MICE; NEURONS; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; RATS;

EID: 77951205245     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.021     Document Type: Article

References (48)

1. Barnes C.A., Meltzer J., Houston F., Orr G., McGann K., Wenk G.L. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 2000, 99:17-23.
2. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-414.
3. Bickel U., Thomsen T., Fischer J.P., Weber W., Kewitz H. Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 1991, 30:447-454.
4. Bores G.M., Huger F.P., Petko W., Mutlib A.E., Camacho F., Rush D.K., Selk D.E., Wolf V., Kosley R.W., Davis L., Vargas H.M. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J. Pharmacol. Exp. Ther. 1996, 277:728-738.
5. Caricati-Neto A., D'Angelo L.C., Reuter H., Hyppolito Jurkiewicz N., Garcia A.G., Jurkiewicz A. Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens. Eur. J. Pharmacol. 2004, 503:191-201.
6. + current and enhances induction of long-term potentiation in hippocampal CA1 pyramidal neurons. J. Neurosci. 2006, 26:12143-12151.
7. Colom L.V., Diaz M.E., Beers D.R., Neely A., Xie W.J., Appel S.H. Role of potassium channels in amyloid-induced cell death. J. Neurochem. 1998, 70:1925-1934.
8. Costa P.F., Santos A.I., Ribeiro M.A. Potassium currents in acutely isolated maturing rat hippocampal CA1 neurones. Brain Res. Dev. Brain Res. 1994, 83:216-223.
9. Etcheberrigaray R., Ito E., Oka K., Tofel-Grehl B., Gibson G.E., Alkon D.L. Potassium channel dysfunction in fibroblasts identifies patients with Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:8209-8213.
10. + channels. Science 1994, 264:276-279.
11. Farlow M.R. Clinical pharmacokinetics of galantamine. Clin. Pharmacokinet. 2003, 42:1383-1392.
12. Fenwick E.M., Marty A., Neher E. Sodium and calcium channels in bovine chromaffin cells. J. Physiol. 1982, 331:599-635.
13. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 1999, 66:137-147.
14. + currents in rat cultured striatal neurons. Pflugers Arch. 1997, 434:642-645.
15. Inan S.Y., Aksu F., Baysal F. The effects of some K(+) channel blockers on scopolamine- or electroconvulsive shock-induced amnesia in mice. Eur. J. Pharmacol. 2000, 407:159-164.
16. Jann M.W., Shirley K.L., Small G.W. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet. 2002, 41:719-739.
17. Kraliz D., Singh S. Selective blockade of the delayed rectifier potassium current by tacrine in Drosophila. J. Neurobiol. 1997, 32:1-10.
18. Li Y., Hu G.Y. Huperzine A inhibits the sustained potassium current in rat dissociated hippocampal neurons. Neurosci. Lett. 2002, 329:153-156.
19. Lilienfeld S. Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002, 8:159-176.
20. + currents in differentiated N1E-115 neuroblastoma cells. Eur. J. NeuroSci. 2008, 27:2019-2032.
21. Lisman J. Long-term potentiation: outstanding questions and attempted synthesis. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2003, 358:829-842.
22. Maelicke A., Coban T., Storch A., Schrattenholz A., Pereira E.F., Albuquerque E.X. Allosteric modulation of Torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists. J. Recept. Signal Transduct. Res. 1997, 17:11-28.
23. Marco-Contelles J., do Carmo Carreiras M., Rodriguez C., Villarroya M., Garcia A.G. Synthesis and pharmacology of galantamine. Chem. Rev. 2006, 106:116-133.
24. Misonou H., Mohapatra D.P., Park E.W., Leung V., Zhen D., Misonou K., Anderson A.E., Trimmer J.S. Regulation of ion channel localization and phosphorylation by neuronal activity. Nat. Neurosci. 2004, 7:711-718.
25. Misonou H., Mohapatra D.P., Menegola M., Trimmer J.S. Calcium- and metabolic state-dependent modulation of the voltage-dependent Kv2.1 channel regulates neuronal excitability in response to ischemia. J. Neurosci. 2005, 25:11184-11193.
26. Moriguchi S., Marszalec W., Zhao X., Yeh J.Z., Narahashi T. Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. J. Pharmacol. Exp. Ther. 2004, 310:933-942.
27. + channel alters voltage-dependent activation. Mol. Pharmacol. 1997, 52:821-828.
28. Oh M.M., Wu W.W., Power J.M., Disterhoft J.F. Galantamine increases excitability of CA1 hippocampal pyramidal neurons. Neuroscience 2006, 137:113-123.
29. + currents in dissociated rat hippocampal neurons. Br. J. Pharmacol. 2003, 140:907-912.
30. Pan Y.P., Xu X.H., Wang X.L. Galantamine blocks delayed rectifier, but not transient outward potassium current in rat dissociated hippocampal pyramidal neurons. Neurosci. Lett. 2003, 336:37-40.
31. + current by trypsin, alkaline pH, and anions. Am. J. Physiol. 1998, 275:H751-H759.
32. Ramakers G.M., Storm J.F. A postsynaptic transient K(+) current modulated by arachidonic acid regulates synaptic integration and threshold for LTP induction in hippocampal pyramidal cells. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10144-10149.
33. Raskind M.A., Peskind E.R., Wessel T., Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000, 54:2261-2268.
34. Sakmann B., Neher E. Single-channel Recording 1995, Plenum, New York. 2nd ed.
35. Samochocki M., Zerlin M., Jostock R., Groot Kormelink P.J., Luyten W.H., Albuquerque E.X., Maelicke A. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol. Scand. Suppl. 2000, 176:68-73.
36. Santos M.D., Alkondon M., Pereira E.F., Aracava Y., Eisenberg H.M., Maelicke A., Albuquerque E.X. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol. Pharmacol. 2002, 61:1222-1234.
37. Schilstrom B., Ivanov V.B., Wiker C., Svensson T.H. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 2007, 32:43-53.
38. Schrattenholz A., Pereira E.F., Roth U., Weber K.H., Albuquerque E.X., Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 1996, 49:1-6.
39. Sweeney J.E., Puttfarcken P.S., Coyle J.T. Galanthamine, an acetylcholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice. Pharmacol. Biochem. Behav. 1989, 34:129-137.
40. Thomsen T., Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci. 1990, 46:1553-1558.
41. Thomsen T., Kaden B., Fischer J.P., Bickel U., Barz H., Gusztony G., Cervos-Navarro J., Kewitz H. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur. J. Clin. Chem. Clin. Biochem. 1991, 29:487-492.
42. Wilcock G.K., Lilienfeld S., Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000, 321:1445-1449.
43. Yu B., Hu G.Y. Donepezil blocks voltage-gated ion channels in rat dissociated hippocampal neurons. Eur. J. Pharmacol. 2005, 508:15-21.
44. Yu S.P., Farhangrazi Z.S., Ying H.S., Yeh C.H., Choi D.W. Enhancement of outward potassium current may participate in beta-amyloid peptide-induced cortical neuronal death. Neurobiol. Dis. 1998, 5:81-88.
45. Zhang H.X., Zhang W., Jin H.W., Wang X.L. Galantamine blocks cloned Kv2.1, but not Kv1.5 potassium channels. Brain Res. Mol. Brain Res. 2004, 131:136-140.
46. Zhang L., Zhou F.M., Dani J.A. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol. Pharmacol. 2004, 66:538-544.
47. Zhang W., Jin H.W., Wang X.L. Effects of presenilins and beta-amyloid precursor protein on delayed rectifier potassium channels in cultured rat hippocampal neurons. Acta Pharmacol. Sin. 2004, 25:181-185.
48. Zhong C.B., Zhang W., Wang X.L. Effects of donepezil on the delayed rectifier-like potassium current in pyramidal neurons of rat hippocampus and neocortex. Yao Xue Xue Bao 2002, 37:415-418.